DK2275134T3 - Anvendelse af adcc-optimerede antistoffer til behandling af svækkede patienter - Google Patents
Anvendelse af adcc-optimerede antistoffer til behandling af svækkede patienter Download PDFInfo
- Publication number
- DK2275134T3 DK2275134T3 DK10181317.8T DK10181317T DK2275134T3 DK 2275134 T3 DK2275134 T3 DK 2275134T3 DK 10181317 T DK10181317 T DK 10181317T DK 2275134 T3 DK2275134 T3 DK 2275134T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- antibodies
- patients
- fcgr3a
- use according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (16)
1. Anvendelse af en sammensætning af kimære, humaniserede, eller humane monoklonale antistoffer, der er rettet mod et antigen af en patogen organisme over for mennesker, hvilken sammensætning i glycan-strukturen af Fc-domænet af antistoffet har et indhold af formerne GO + GI + GOF + GIF, der er på over 60 %, og et indhold af formerne GOF + GIF, der er mindre end 50 %, til fremstilling af et lægemiddel, der er beregnet til behandling af infektioner med den patogene organisme i patienter, der er homozygote for phenylalanin i position 158 af CD16 (FCGR3A-158F homozygoter) , eller i patienter, der er heterozygote for valin/phenylalanin i position 158 af CD16 (FCGR3A-158V/F).
2. Anvendelse ifølge krav 1, kendetegnet ved, at antistoffet er et antistof, som er rettet mod en celle, der er inficeret med et virus, og som er beregnet til behandling af infektioner af virusset.
3. Anvendelse ifølge krav 2, kendetegnet ved, at antistoffet er et antistof mod HIV og er beregnet til behandling af HIV-infektioner.
4. Anvendelse ifølge krav 2, kendetegnet ved, at antistoffet er et antistof mod RSV og er beregnet til behandling af RSV-infektioner.
5. Anvendelse ifølge ethvert af kravene 1 til 4, kendetegnet ved, at den nævnte sammensætning har et indhold af formerne GO + GI + GOF + GIF, der er på over 80 %.
6. Anvendelse ifølge ethvert af kravene 1 til 5, kendetegnet ved, at formerne GOF + GIF foreligger med mindre end 30 %.
7. Anvendelse ifølge ethvert af kravene 1 til 6, kendetegnet ved, at antistofferne er IgGl.
8. Anvendelse ifølge ethvert af kravene 1 til 7, kendetegnet ved, at patienterne er homozygote for phenylalanin i position 158 af CD16 (FCGR3A-158F homozygoter).
9. Sammensætning af kimære, humaniserede eller humane monoklonale antistoffer, der er rettet mod et antigen af en patogen organisme over for mennesker, hvilken sammensætning i glycanstrukturen af Fc-domænet af antistoffet har et indhold af formerne GO + GI + GOF + GIF, der er på over 60 %, og et indhold af formerne GOF + GIF, der er mindre end 50 %, til anvendelse deraf ved behandlingen af infektioner af den nævnte patogene organisme i patienter, der er homozygote for phenylalanin i position 158 af CD16 (FCGR3A-158F homozygoter) , eller i patienter, der er heterozygote for valin/phenylalanin i position 158 af CD16 (FCGR3A-158V/F).
10. Sammensætning til anvendelse ifølge krav 9, kendetegnet ved, at antistoffet er et antistof, som er rettet mod en celle, der er inficeret med et virus, og som er beregnet til behandling af infektioner af virusset.
11. Sammensætning til anvendelse ifølge krav 10, kendetegnet ved, at antistoffet er et antistof mod HIV og er beregnet til behandling af HIV-infektioner.
12. Sammensætning til anvendelse ifølge krav 10, kendetegnet ved, at antistoffet er et antistof mod RSV og er beregnet til behandling af RSV-infektioner.
13. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 9 til 12, kendetegnet ved, at den nævnte sammensætning har et indhold af formerne GO + GI + GOF + GIF, der er på over 80 %.
14. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 9 til 13, kendetegnet ved, at formerne GOF + GIF foreligger med mindre end 30 %.
15. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 9 til 14, kendetegnet ved, at antistofferne er IgGl.
16. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 9 til 15, kendetegnet ved, at patienterne er homozygote for phenylalanin i position 158 af CD16 (FCGR3A-158F homozygoter).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0309440A FR2858235B1 (fr) | 2003-07-31 | 2003-07-31 | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| EP04786018.4A EP1648513B1 (fr) | 2003-07-31 | 2004-07-30 | Utilisation d'anticorps ayant une adcc optimisée pour traiter les patients répondant faiblement au traitement par antocorps. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2275134T3 true DK2275134T3 (da) | 2017-05-22 |
Family
ID=34043702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04786018.4T DK1648513T3 (da) | 2003-07-31 | 2004-07-30 | Anvendelsen af ADCC-optimerede antistoffer til behandling af patienter, som reagerer svagt på behandling med antistoffer |
| DK10181317.8T DK2275134T3 (da) | 2003-07-31 | 2004-07-30 | Anvendelse af adcc-optimerede antistoffer til behandling af svækkede patienter |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04786018.4T DK1648513T3 (da) | 2003-07-31 | 2004-07-30 | Anvendelsen af ADCC-optimerede antistoffer til behandling af patienter, som reagerer svagt på behandling med antistoffer |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7713524B2 (da) |
| EP (3) | EP2275134B1 (da) |
| JP (3) | JP5252525B2 (da) |
| AU (1) | AU2004261754C1 (da) |
| BR (1) | BRPI0413119A (da) |
| CA (1) | CA2533918C (da) |
| DK (2) | DK1648513T3 (da) |
| ES (3) | ES2822930T3 (da) |
| FR (1) | FR2858235B1 (da) |
| IL (1) | IL173386A0 (da) |
| PL (1) | PL1648513T3 (da) |
| WO (1) | WO2005012358A2 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| US20090181016A1 (en) * | 2005-11-30 | 2009-07-16 | University Of Southern California | FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME |
| FR2895086B1 (fr) * | 2005-12-16 | 2012-10-05 | Lab Francais Du Fractionnement | Potentialisation de l'apoptose par des anticorps monoclonaux |
| EP1878747A1 (en) * | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| WO2008088854A2 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
| FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
| EP2340305A1 (en) * | 2008-09-26 | 2011-07-06 | Eureka Therapeutics, Inc. | Cell lines and proteins with variant glycosylation pattern |
| US8883496B2 (en) | 2009-12-21 | 2014-11-11 | Regeneron Phamaceuticals, Inc. | Humanized FcgR mice |
| SI2516457T1 (en) * | 2009-12-21 | 2018-08-31 | Regeneron Pharmaceuticals, Inc. | MUSHROOM WITH HUMANIZED FC GAMES R |
| DK3138581T3 (da) | 2011-03-17 | 2019-04-15 | Univ Birmingham | Omdirigeret immunterapi |
| CN103687872A (zh) | 2011-04-22 | 2014-03-26 | 新兴产品开发西雅图有限公司 | 前列腺特异性膜抗原结合蛋白和相关组合物以及方法 |
| UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
| AU2013291964B2 (en) | 2012-07-18 | 2017-12-14 | Glycotope Gmbh | Novel therapeutic treatments with anti-HER2 antibodies having a low fucosylation |
| CA2890176C (en) | 2012-11-02 | 2021-12-14 | Tg Therapeutics, Inc. | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
| FR3003172B1 (fr) * | 2013-03-15 | 2017-12-08 | Lab Francais Du Fractionnement | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| SG11201507743XA (en) | 2013-04-22 | 2015-11-27 | Glycotope Gmbh | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
| SG11201604886WA (en) | 2014-04-08 | 2016-07-28 | Regeneron Pharma | Non-human animals having humanized fc-gamma receptors |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| EP3402885A4 (en) | 2016-01-11 | 2019-07-03 | The Board of Trustees of the Leland Stanford Junior University | CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION |
| CN108463229B (zh) | 2016-01-11 | 2023-10-17 | 斯坦福大学托管董事会 | 嵌合蛋白和免疫治疗方法 |
| CN109640964A (zh) | 2016-05-27 | 2019-04-16 | Tg治疗有限公司 | 用于治疗B细胞增殖性紊乱的抗-CD20抗体、P13激酶-δ选择性抑制剂和BTK抑制剂的组合 |
| US20190247399A1 (en) | 2016-09-09 | 2019-08-15 | Tg Therapeutics, Inc. | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
| SG11202008620VA (en) | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
| JP2022521610A (ja) | 2019-02-26 | 2022-04-11 | ヤンセン バイオテツク，インコーポレーテツド | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
| WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| WO2022104150A1 (en) | 2020-11-12 | 2022-05-19 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9305557A (pt) * | 1992-06-26 | 1997-03-25 | Aetsrn | Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém |
| ES2568899T3 (es) * | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| WO2001064754A1 (fr) * | 2000-03-03 | 2001-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps a recombinaison genique et son fragment |
| FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| EP3690043A1 (en) | 2000-10-06 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Antibody composition-producing cell |
| ATE349028T1 (de) * | 2001-07-09 | 2007-01-15 | E Ink Corp | Elektrooptische anzeige und kleberzusammensetzung |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| EP1502603A4 (en) * | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
| FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| FR2858235B1 (fr) * | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
-
2003
- 2003-07-31 FR FR0309440A patent/FR2858235B1/fr not_active Expired - Lifetime
-
2004
- 2004-07-30 US US10/566,358 patent/US7713524B2/en active Active
- 2004-07-30 AU AU2004261754A patent/AU2004261754C1/en not_active Expired
- 2004-07-30 DK DK04786018.4T patent/DK1648513T3/da active
- 2004-07-30 EP EP10181317.8A patent/EP2275134B1/fr not_active Expired - Lifetime
- 2004-07-30 WO PCT/FR2004/002057 patent/WO2005012358A2/fr active Application Filing
- 2004-07-30 ES ES16203349T patent/ES2822930T3/es not_active Expired - Lifetime
- 2004-07-30 JP JP2006521632A patent/JP5252525B2/ja not_active Expired - Lifetime
- 2004-07-30 ES ES04786018.4T patent/ES2525680T3/es not_active Expired - Lifetime
- 2004-07-30 EP EP16203349.2A patent/EP3159008B1/fr not_active Expired - Lifetime
- 2004-07-30 EP EP04786018.4A patent/EP1648513B1/fr not_active Revoked
- 2004-07-30 DK DK10181317.8T patent/DK2275134T3/da active
- 2004-07-30 PL PL04786018T patent/PL1648513T3/pl unknown
- 2004-07-30 ES ES10181317.8T patent/ES2624272T3/es not_active Expired - Lifetime
- 2004-07-30 BR BRPI0413119-3A patent/BRPI0413119A/pt not_active Application Discontinuation
- 2004-07-30 CA CA2533918A patent/CA2533918C/fr not_active Expired - Lifetime
-
2006
- 2006-01-26 IL IL173386A patent/IL173386A0/en not_active IP Right Cessation
-
2010
- 2010-03-23 US US12/659,824 patent/US8501171B2/en active Active
-
2011
- 2011-09-13 JP JP2011199174A patent/JP5788273B2/ja not_active Expired - Lifetime
-
2013
- 2013-06-28 US US13/930,070 patent/US9109020B2/en active Active
-
2014
- 2014-11-28 JP JP2014241534A patent/JP6078519B2/ja not_active Expired - Lifetime
-
2015
- 2015-05-01 US US14/702,143 patent/US9879089B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2275134T3 (da) | Anvendelse af adcc-optimerede antistoffer til behandling af svækkede patienter | |
| US20090081216A1 (en) | Treatment of pathologies which escape the immune response, using optimized antibodies | |
| JP2006516951A (ja) | Ａｄｃｃおよびサイトカイン産生の誘導のための抗体 | |
| AU2008257271A1 (en) | Set of means for treating a malignant pathology, an autoimmune disease or an infectious disease | |
| US20150368357A1 (en) | Highly galactosylated anti-her2 antibodies and uses thereof | |
| Miller et al. | Identification of human T cells that require zinc for growth | |
| JP4368800B2 (ja) | サイトカイン産生誘導抗体 | |
| KNOBLOCH et al. | Allorecognition and T cell repertoire selection in severe combined immunodeficiency lacking HLA class II antigens | |
| JP2009519302A (ja) | モノクローナル抗体によるアポトーシスの増強作用 |